Outlook Therapeutics, Inc. (OTLK) is gearing up for a series of key catalysts over the coming months that could significantly impact the company's trajectory, especially regarding its lead product, LYTENAVA.
LYTENAVA is an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration or wet AMD.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com